Bioqual Stock Price, News & Analysis

BIOQUAL, Inc. announces the retirement of CFO Dave Newcomer, effective June 3, 2022, after serving since 1994. He will remain to aid in the transition to his successor, Charles (Chris) C. Kirk, Jr., who has over 25 years of financial experience. Newcomer will also join the Board of Directors following his retirement to utilize his company knowledge. This leadership transition emphasizes continuity as BIOQUAL addresses market challenges, including government contracts and demand for animal models in research.

BIOQUAL, Inc. has announced the appointment of Hanne Andersen Elyard, PhD, as its first Chief Scientific Officer, a role aimed at enhancing the company’s contract research efforts in infectious diseases. With over 17 years at BIOQUAL, Dr. Elyard is expected to lead the expansion of preclinical testing models and laboratory analysis. CEO Mark Lewis expressed confidence in her leadership capabilities, noting her extensive experience in microbiology and contract research. The PR also includes forward-looking statements about potential risks and uncertainties affecting the company's operations.

BIOQUAL, Inc. (OTC-Pink: BIOQ) reported significant financial results for the nine months ended February 28, 2022, with revenue of $47.81 million, a 16.7% increase compared to $41.07 million in the same period of 2021. Net income for the nine months was $3.37 million, with basic earnings per share at $3.77 and diluted earnings per share also at $3.77. In the three months ended February 28, 2022, the company achieved revenue of $17.13 million, up from $12.58 million in 2021, and net income reached $856,588, demonstrating profitability growth in a competitive market.

BIOQUAL, Inc. (OTC-Pink: BIOQ) reported its financial results for the six months and three months ended November 30, 2021. Revenue for the six months was $30.67 million, an increase from $28.49 million in the previous year. The company recorded a net income of $2.52 million, compared to $3.23 million year-over-year. Earnings per share were $2.81 basic and diluted. The results reflect a solid performance with a 9% revenue growth, but a decline in net income indicates potential cost management challenges going forward.

BIOQUAL, Inc. (OTC-PINK:BIOQ) reported its financial results for the three months ended August 31, 2021. The company achieved revenue of $15,472,759, a rise from $14,920,475 in the same period of 2020. Despite the increase in revenue, net income declined to $1,377,005 compared to $1,766,588 in the prior year. The basic earnings per share decreased to $1.54 from $1.98. The company emphasizes ongoing risks and uncertainties that could impact future performance.

BIOQUAL, Inc. (OTC-Pink:BIOQ) reported significant financial growth for the fiscal year 2021, with revenues reaching $57.68 million, up from $46.36 million in 2020. The net income also saw an increase to $6.33 million compared to $4.23 million the previous year. The company declared a $1.25 per share dividend for shareholders of record as of September 29, 2021, payable on October 20, 2021. This marks the twentieth dividend declaration by BIOQUAL, reflecting its commitment to returning value to shareholders.

BIOQUAL, Inc. (OTC-Pink:BIOQ) reported strong financial results for the nine months ended February 28, 2021, with revenues reaching $41,070,486, up from $32,884,055 in the prior year. Net income rose to $4,203,962, compared to $2,936,730 last year. Basic and diluted earnings per share increased significantly to $4.70 and $4.70, respectively. For the third quarter alone, revenues were $12,584,303, higher than $11,593,217 in the same quarter of the previous year. This reflects strong year-over-year growth and improved profitability.

Dr. John C. Landon, former president, CEO, and chairman of the board of BIOQUAL, passed away on January 10, 2021, at age 84. A distinguished biologist, he contributed significantly to cancer research and led BIOQUAL from a small enterprise to a $20 million life sciences corporation. Under his leadership, BIOQUAL expanded its services to include pivotal roles in vaccine and therapeutic research, notably in combating COVID-19. His legacy is marked by advancements in biomedical research and his dedication to enhancing global health.

BIOQUAL, Inc. (OTC Pink: BIOQ) reported its unaudited second quarter results for fiscal year 2021. Revenue increased to $28,486,183 for the six months ended November 30, 2020, compared to $21,290,838 for the same period in 2019. Net income also rose to $3,228,002, up from $2,216,324 year-over-year. The company reported basic earnings per share of $3.61 for the period, reflecting a solid financial performance despite ongoing risks related to government contracts and reliance on third-party services.